FILTER

Refine your search with the following facets to narrow down your results.

9 Current news of Protox Therapeutics

Protox announces positive Phase 2b BPH results

13-Jan-2010 - Protox Therapeutics Inc. announced positive top-line results from its double-blinded placebo controlled Phase 2b study of PRX302 (study name: TRIUMPH) in patients with moderate to severe benign prostatic hyperplasia (BPH). The study achieved its primary clinical endpoint of a statistically ...

benign prostatic hyperplasia benign prostatic hypertrophy flow +2

Protox completes enrollment of Phase 2b BPH trial

10-Sep-2009 - Protox Therapeutics Inc. announced that it has completed patient enrollment in its multi-centre, double-blinded, placebo controlled Phase 2b study of PRX302 (study name: TRIUMPH) in males with moderate to severe benign prostatic hyperplasia (BPH). TRIUMPH is the third BPH clinical trial of ...

benign prostatic hyperplasia benign prostatic hypertrophy clinical trials +2

Protox doses first patient in Phase 2 BPH clinical trial

19-May-2008 - Protox Therapeutics Inc. announced the enrolment and successful dosing of the first patient in a Phase 2 clinical trial evaluating PRX302 to treat benign prostatic hyperplasia (BPH), or enlarged prostate. "This milestone sets the stage for a very exciting time for Protox this year as we embark ...

benign prostatic hyperplasia benign prostatic hypertrophy clinical trials +1

Protox announces positive long-term data from BPH study

21-Apr-2008 - Protox Therapeutics Inc. announced positive results from its Phase 1 study evaluating PRX302 in patients with benign prostatic hyperplasia (BPH), a common and bothersome urological condition among the aging male population. The results indicate that promising signs of therapeutic activity ...

benign prostatic hyperplasia benign prostatic hypertrophy clinical trials +4

Protox announces positive final results from BPH study

07-Jan-2008 - Protox(TM) Therapeutics Inc. announced positive final results from its Phase 1 study evaluating PRX302 in patients with benign prostatic hyperplasia (BPH), a common condition among the aging male population. The trial results indicate that PRX302 is safe and well tolerated and shows very ...

benign prostatic hyperplasia benign prostatic hypertrophy dosing +6

Protox acquires research program from Medicenna

23-Aug-2007 - Protox Therapeutics Inc. announced that it has entered into an asset purchase agreement with Medicenna Ventures Inc. for the acquisition of Medicenna's HUMxin(TM) Program, a research program to develop fully humanized fusion proteins based upon the Bcl-2 family, which are key components of ...

apoptosis diseases fusion proteins +3

Protox files foundation patent for PORxin(TM) technology

15-Dec-2005 - Protox Therapeutics Inc. announced that it has filed a provisional patent application with the United States Patent and Trademark Office entitled "Modified Pore-Forming Toxins and Use Thereof". This is a foundational patent application, intended to encompass and protect several aspects of the ...

diseases

Protox signs exclusive Lung Cancer licence agreement and initiates Lung Cancer study

11-Aug-2005 - Protox Therapeutics Inc. announced that it has signed an exclusive licence agreement with the National Research Council Institute for Biological Sciences (NRC-IBS) and the University of Victoria (UVic) Innovation and Development Corporation (IDC). The licence grants Protox exclusive worldwide ...

lung cancer

Protox receives funding from NRC to develop lung cancer drug

09-Jun-2005 - Protox Therapeutics Inc. announced that it has received a financial contribution of up to $340,000 from the National Research Council ('NRC') Industrial Research Assistance Program ('IRAP'). The NRC has committed this money to the Company to support its development of Lung-H1, a therapeutic toxin ...

antibodies lung cancer